(Reuters) – The U.S. government said on Wednesday it will subject 27 drugs to inflation penalties, a move that will require the pharmaceutical companies to pay Medicare rebates if they raise prices at a faster pace than the rise in inflation rate.
Under the new provisions, the government will start invoicing the companies for the rebates in 2025, but Medicare members will see a reduction in out-of-pocket costs starting April.
Here is a list of the drugs and companies:
DRUG NAME USED FOR MANUFACTURER U.S. NET
SALES IN
2022
Humira Arthritis AbbVie Inc $18.62
billion
Yescarta Blood cancer Gilead Sciences $747
Inc million
Padcev Urothelial cancer Seagen Inc $451
million
Xiaflex Peyronie’s disease Endo $438.7
International million
Plc
Tecartus Blood cancer Gilead Sciences $221
Inc million
Mircera Anemia Roche 408 million
Swiss
Francs
($442.66
million) in
global
sales
Fetroja Serious bladder or Shionogi & Co 7.3 billion
kidney infections Ltd yen in
in adults Apr-Dec
2022 ($54.6
million)
Fragmin Treat blood clots Pfizer Inc $4 million
Abelcet Invasive fungal Leadiant Data
infections Biosciences unavailable
Akynzeo Prevention of Helsinn Data
chemotherapy-induce Healthcare S.A unavailable
d nausea and
vomiting
Atgam Used after kidney Pfizer Inc Data
transplant to keep unavailable
the body from
rejecting the organ
Aveed Treat low Endo Data
testosterone in International unavailable
adult males Plc
Bicillin Antibiotic Pfizer Inc Data
C-R unavailable
Bicillin Antibiotic Pfizer Inc Data
L-A unavailable
Carnitor Carnitine Leadiant Data
deficiency Biosciences unavailable
Cytogam To prevent a Kamada Ltd Data
cytomegalovirus unavailable
disease infection
in transplant
patients
Elzonris Rare form of blood Menarini Group Data
cancer unavailable
Flebogamma Treatment for Grifols SA Data
DIF primary unavailable
immunodeficiency
and autoimmune
disease
Folotyn T-cell lymphoma Acrotech Data
Biopharma LLC unavailable
Leukine Blood cancer Partner Data
Therapeutics unavailable
Minocin To prevent Bausch Health Data
infections in Companies unavailable
hospitalized
patients
Nipent Blood cancer Pfizer Inc Data
unavailable
Rybrevant Lung cancer Johnson & Data
Johnson unavailable
Signifor For the rare Recordati Data
LAR diseases Acromegaly unavailable
and Cushing’s
disease
Sylvant Multicentric EUSA Pharma (US) Data
Castleman’s disease LLC unavailable
Winrho SDF Bleeding disorder Kamada Ltd’s Data
unavailable
Xipere Eye disease macular Bausch and Data
edema associated Lomb’s unavailable
with uveitis
($1 = 0.9217 Swiss francs)
(Compiled by Aditya Samal and Leroy leo; Editing by Shinjini Ganguli)
